Unknown

Dataset Information

0

The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation.


ABSTRACT:

Background

The impact of gene mutations typically associated with myelodysplastic syndrome (MDS) in acute myeloid leukemia (AML) with NPM1 mutation is unclear.

Methods

Using a cohort of 107 patients with NPM1-mutated AML treated with risk-adapted therapy, we compared survival outcomes of patients without MDS-related gene mutations (group A) with those carrying concurrent FLT3-ITD (group B) or with MDS-related gene mutations (group C). Minimal measurable disease (MMD) status assessed by multiparameter flow cytometry (MFC), polymerase chain reaction (PCR), and/or next-generation sequencing (NGS) were reviewed.

Results

Among the 69 patients treated intensively, group C showed significantly inferior progression-free survival (PFS, p < 0.0001) but not overall survival (OS, p = 0.055) compared to group A. Though groups A and C had a similar MMD rate, group C patients had a higher relapse rate (p = 0.016). Relapse correlated with MMD status at the end of cycle 2 induction (p = 0.023). Survival of group C patients was similar to that of group B.

Conclusion

MDS-related gene mutations are associated with an inferior survival in NPM1-mutated AML.

SUBMITTER: Wang Y 

PROVIDER: S-EPMC9818485 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying <i>NPM1</i> Mutation.

Wang Yi Y   Quesada Andres E AE   Zuo Zhuang Z   Medeiros L Jeffrey LJ   Yin C Cameron CC   Li Shaoying S   Xu Jie J   Borthakur Gautam G   Li Yisheng Y   Yang Chao C   Abaza Yasmin Y   Gao Juehua J   Lu Xinyan X   You M James MJ   Zhang Yizhuo Y   Lin Pei P  

Cancers 20221229 1


Background: The impact of gene mutations typically associated with myelodysplastic syndrome (MDS) in acute myeloid leukemia (AML) with NPM1 mutation is unclear. Methods: Using a cohort of 107 patients with NPM1-mutated AML treated with risk-adapted therapy, we compared survival outcomes of patients without MDS-related gene mutations (group A) with those carrying concurrent FLT3-ITD (group B) or with MDS-related gene mutations (group C). Minimal measurable disease (MMD) status assessed by multipa  ...[more]

Similar Datasets

| S-EPMC7659109 | biostudies-literature
| S-EPMC10548603 | biostudies-literature
| S-EPMC6497712 | biostudies-literature
| S-EPMC8945292 | biostudies-literature
| S-EPMC5477628 | biostudies-literature
| S-EPMC3830788 | biostudies-literature
2017-05-03 | E-GEOD-68469 | biostudies-arrayexpress
| S-EPMC3767041 | biostudies-literature